Restricted accessResearch articleFirst published online 2018
Age-Dependent Changes in the Sarkosyl-Insoluble Proteome of APP SWE /PS1 ΔE9 Transgenic Mice Implicate Dysfunctional Mitochondria in the Pathogenesis of Alzheimer’s Disease
Alzheimer’s disease (AD), the most common cause of dementia, is characterized by the intra- and extracellular aggregation and accumulation of proteins. The major molecular hallmark is the aggregation of amyloid-β (Aβ) and hyperphosphorylated tau proteins into plaques and tangles, respectively. Evidence points to the pre-fibrillary states of protein aggregates harboring the greatest neurotoxicity.
Objective:
This study was designed to identify and quantify pre-fibrillary protein species enriched by their insolubility in the detergent sarkosyl in the APPSWE/PS1ΔE9 (APP/PS1) transgenic mouse model of AD. Sarkosyl insoluble fractions were isolated from the brains of APP/PS1 and littermate wild type (Wt) mice to identify pre-fibrillary protein species associated with AD.
Methods:
Pre-fibrillary protein species were isolated from the brains of 3- and 24-month-old APP/PS1 and littermate Wt mice using sarkosyl extraction and subjected to quantitative proteomics analysis by the use of isobaric tags for relative and absolute quantitation (iTRAQ).
Results:
The sarkosyl-insoluble pre-fibrillary proteome showed differential age- and genotype-induced effects. In addition to Aβ and tau, old APP/PS1 mice showed significant enrichment in proteins in the sarkosyl fraction involved in oxidative phosphorylation and mitochondrial function.
Conclusion:
The results of this study implicate dysfunctional mitochondria as playing a key role of Aβ- and potentially tau-induced pathological events in the APP/PS1 transgenic mouse model of AD.
PrinceM, Comas-HerreraA, KnappM, GuerchetM, KaragiannidouM (2016) World Alzheimer Report 2016: Improving healthcare for people living with dementia. Coverage. Quality and costs now and in the future. Alzheimer's Disease International, London.
2.
BayerTA (2015) Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?Eur Neuropsychopharmacol25, 713–724.
3.
GoldeTE, SchneiderLS, KooEH (2011) Anti-Aβ therapeutics in Alzheimer’s disease: The need for a paradigm shift. Neuron69, 203–213.
4.
ArriagadaPV, GrowdonJH, Hedley-WhyteET, HymanBT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42(3 Pt 1), 631–639.
5.
BennettDA, SchneiderJA, WilsonRS, BieniasJL, ArnoldSE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol61, 378–384.
6.
ChiotisK, Saint-AubertL, SavitchevaI, JelicV, AndersenP, JonassonM, ErikssonJ, LubberinkM, AlmkvistO, WallA, AntoniG, NordbergA (2016) Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging43, 1686–1699.
Spires-JonesTL, KopeikinaKJ, KoffieRM, deCalignon A, HymanBT (2011) Are tangles as toxic as they look?J Mol Neurosci45, 438–444.
9.
SelenicaMB, BrownlowM, JimenezJP, LeeDC, PenaG, DickeyCA, GordonMN, MorganD (2013) Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy. Neurodegener Dis11, 165–181.
10.
Castillo-CarranzaDL, Guerrero-MunozMJ, SenguptaU, HernandezC, BarrettADT, DineleyK, KayedR (2015) Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer’s disease mouse model. J Neurosci35, 4857–4868.
11.
JankowskyJL, SluntHH, RatovitskiT, JenkinsNA, CopelandNG, BorcheltDR (2001) Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng17, 157–165.
12.
BabcockAA, IlkjærL, ClausenBH, VilladsenB, Dissing-OlesenL, BendixenATM, LyckL, LambertsenKL, FinsenB (2015) Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice. Brain Behav Immun48, 86–101.
13.
OlesenLØ, SivasaravanaparanM, SeverinoM, BabcockAA, BouzinovaEV, WestMJ, WiborgO, FinsenB (2017) Neuron and neuroblast numbers and cytogenesis in the dentate gyrus of aged APPswe/PS1dE9transgenic mice: Effect of long-term treatment with paroxetine. Neurobiol Dis104, 50–60.
14.
KuwabaraY, IshizekiM, WatamuraN, TobaJ, YoshiiA, InoueT, OhshimaT (2014) Impairments of long-term depression induction and motor coordination precede Aβ accumulation in the cerebellum of APPswe/PS1dE9 double transgenic mice. J Neurochem130, 432–443.
15.
OrreM, KamphuisW, OsbornLM, JansenAHP, KooijmanL, BossersK, HolEM (2014) Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction. Neurobiol Aging35, 2746–2760.
16.
RuppNJ, Wegenast-BraunBM, RaddeR, CalhounME, JuckerM (2011) Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol Aging32, 2324.e1–2324.e6.
LiuY, YooM-J, SavonenkoA, StirlingW, PriceDL, BorcheltDR, MamounasL, LyonsWE, BlueME, LeeMK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer’s disease. J Neurosci28, 13805–13814.
19.
NikolajsenGN, JensenMS, WestMJ (2011) Cholinergic axon length reduced by 300 meters in the brain of an Alzheimer mouse model. Neurobiol Aging32, 1927–1931.
20.
VolianskisA, KøstnerR, MølgaardM, HassS, JensenMS (2010) Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1ΔE9-deleted transgenic mice model of β-amyloidosis. Neurobiol Aging31, 1173–1187.
21.
O’LearyTP, BrownRE (2009) Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer’s disease. Behav Brain Res201, 120–127.
22.
SavonenkoA, XuGM, MelnikovaT, MortonJL, GonzalesV, WongMPF, PriceDL, TangF, MarkowskaAL, BorcheltDR (2005) Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer’s disease: Relationships to β-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis18, 602–617.
23.
HuangH, NieS, CaoM, MarshallC, GaoJ, XiaoN, HuG, XiaoM (2016) Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice. Age (Omaha)38, 303–322.
24.
KempfSJ, MetaxasA, Ibáñez-veaM, DarveshS, FinsenB, LarsenMR (2016) An integrated proteomics approach shows synaptic plasticity changes in an APP / PS1 Alzheimer’s mouse model.
25.
GreenbergSG, DaviesP (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A87, 5827–5831.
26.
ZhangY, SloanSA, ClarkeLE, CanedaC, PlazaCA, BlumenthalPD, VogelH, SteinbergGK, EdwardsMSB, LiG, DuncanJA, CheshierSH, ShuerLM, ChangEF, GrantGA, GephartMGH, BarresBA (2016) Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron89, 37–53.
27.
McNultyDE, AnnanRS (2008) Hydrophilic interaction chromatography reduces the complexity of the phosphoproteome and improves global phosphopeptide isolation and detection. Mol Cell Proteomics7, 971–980.
28.
Melo-BragaMN, Ibáñez-VeaM, LarsenMR, KulejK (2015) Comprehensive protocol to simultaneously study protein phosphorylation, acetylation, and N-linked sialylated glycosylation. Methods Mol Biol1295, 275–292.
29.
KempfSJ, CasciatiA, BuratovicS, JanikD, ToerneC, UeffingM, NeffF, MoertlS, StenerlöwB, SaranA, AtkinsonMJ, ErikssonP, PazzagliaS, TapioS (2014) The cognitive defects of neonatally irradiated mice are accompanied by changed synaptic plasticity, adult neurogenesis and neuroinflammation. Mol Neurodegener9, 57.
30.
VizcaínoJA, CôtéRG, CsordasA, DianesJA, FabregatA, FosterJM, GrissJ, AlpiE, BirimM, ContellJ, O’KellyG, SchoeneggerA, OvelleiroD, Pérez-RiverolY, ReisingerF, RíosD, WangR, HermjakobH (2013) The PRoteomics IDEntifications (PRIDE) database and associated tools: Status in 2013., D1063-D, Nucleic Acids Res41, 1069.
31.
HuangDW, ShermanBT, LempickiRA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc4, 44–57.
32.
DrummondE, NayakS, FaustinA, PiresG, HickmanRA, AskenaziM, CohenM, HaldimanT, KimC, HanX, ShaoY, SafarJG, UeberheideB, WisniewskiT (2017) Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease. Acta Neuropathol133, 933–954.
33.
SelkoeDJ (2011) Alzheimer’s disease. Cold Spring Harb Perspect Biol3, a004457.
34.
YuJ, TanL (2012) The role of clusterin in Alzheimer’s disease: Pathways, pathogenesis, and therapy. Mol Neurobiol45, 314–326.
35.
KimJ, BasakJ, HoltzmanD (2009) The role of lipoprotein E in Alzheimer’s disease. Neuron63, 287–303.
36.
LevinEC, AcharyaNK, SedeynJC, VenkataramanV, AndreaMRD, WangH, NageleRG (2009) Neuronal expression of vimentin in the Alzheimer’s disease brain may be part of a generalized dendritic damage-response mechanism. Brain Res1298, 194–207.
37.
FlahertyDB, SoriaJP, TomasiewiczHG, WoodJG (2000) Phosphorylation of human tau protein by microtubule-associated kinases: GSK3b and cdk5 are key participants. J Neurosci Res62, 463–472.
38.
ShiQ, GibsonGE (2007) Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis Assoc Disord21, 276–291.
39.
ZhangY, ChenK, SloanSA, BennettML, ScholzeAR, O’KeeffeS, PhatnaniHP, GuarnieriP, CanedaC, RuderischN, DengS, LiddelowSA, ZhangC, DanemanR, ManiatisT, BarresBA, WuJQ (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci34, 11929–11947.
40.
HalesCM, DammerEB, DengQ, DuongDM, GearingM, TroncosoJC, ThambisettyM, LahJJ, ShulmanJM, LeveyAI, SeyfriedNT (2016) Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer’s disease progression. Proteomics16, 3042–3053.
41.
GräffJ, WoldemichaelBT, BerchtoldD, DewarratG, MansuyIM (2012) Dynamic histone marks in the hippocampus and cortex facilitate memory consolidation. Nat Commun3, 991.
42.
FrancisYI, FáM, AshrafH, ZhangH, StaniszewskiA, LatchmanDS, ArancioO (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer’s disease. J Alzheimers Dis18, 131–139.
43.
Bahari-JavanS, SananbenesiF, FischerA (2014) Histone-acetylation: A link between Alzheimer’s disease and post-traumatic stress disorder?Front Neurosci8, 1–7.
44.
MancusoM, CalsolaroV, OrsucciD, CarlesiC, ChoubA, PiazzaS, SicilianoG (2009) Mitochondria, cognitive impairment, and Alzheimer’s disease. Int J Alzheimers Dis2009, 1–8.
SwerdlowRH, KhanSM (2004) A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease. Med Hypotheses63, 8–20.
47.
BlassJP (2000) The mitochondrial spiral. An adequate cause of dementia in the Alzheimer’s syndrome. Ann N Y Acad Sci924, 170–183.
48.
BondaDJ, SmithMA, PerryG, LeeH, WangX, ZhuX (2011) The mitochondrial dynamics of Alzheimer’s disease and Parkinson’s disease offer important opportunities for therapeutic intervention. Curr Pharm Des17, 3374–3380.
49.
XuL-L, ShenY, WangX, WeiL-F, WangP, YangH, WangC-F, XieZ-H, BiJ-Z (2017) Mitochondrial dynamics changes with age in an APPsw/PS1dE9 mouse model of Alzheimer’s disease. Neuroreport28, 222–228.
50.
KaufmanDM, WuX, ScottBA, ItaniOA, VanGilst MR, BruceJE, CrowderCM (2017) Ageing and hypoxia cause protein aggregation in mitochondria. Cell Death Differ24, 1730–1738.
51.
JellingerKA (2013) Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci5, 1–19.
